{"id":"W3203804374","doi":"10.1093/noajnl/vdab142","title":"Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene; Bristol-Myers Squibb","keywords":"Bevacizumab; Medicine; Internal medicine; Safety profile; Clinical trial; Phases of clinical research; Adverse effect; Oncology; Gastroenterology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001507598,0.001163178,0.001822932,0.0003510813,0.000276488,0.0007887727,0.0006281718,0.0008266962,0.003494429],"category_scores_gemma":[0.001357648,0.0003414224,0.001532083,0.000562936,0.0003677985,0.0003970062,0.000207848,0.001574362,0.0006586146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007396152,"about_ca_system_score_gemma":0.00122254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001327188,"about_ca_topic_score_gemma":0.005276617,"domain_scores_codex":[0.9994987,0.0002674697,0.00004866347,0.00006771903,0.00005930513,0.00005809543],"domain_scores_gemma":[0.9993306,0.0001110131,0.0002243948,0.00004145435,0.00007741295,0.0002150628],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6369488,0.01241293,0.01044259,0.006495368,0.0116741,0.0004136713,0.0001614984,0.00302983,0.04478168,0.0003122266,0.02218584,0.2511415],"study_design_scores_gemma":[0.6893294,0.2305539,0.03914979,0.0006469276,0.008494021,0.0006798669,0.00007737104,0.002463116,0.006820337,0.0005572644,0.02114294,0.00008497935],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9114946,0.06732552,0.001424557,0.002746451,0.0005698541,0.004008268,0.005160541,0.0003253425,0.00694485],"genre_scores_gemma":[0.9585075,0.02514236,0.001765384,0.002296894,0.0004814089,0.00294856,0.005875381,0.00006164402,0.002920813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003494429,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0504961663408643,"score_gpt":0.3912912240822793,"score_spread":0.340795057741415,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}